

Immunohistochemistry (IHC)

EviCore
By EVERNORTH

- This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance.
- Based upon the clinical policy, following EviCore's criteria for immunohistochemistry (IHC) will ensure that testing will be available to those members most likely to benefit from the information provided by the assay. For those not meeting criteria, it ensures alternate diagnostic/management strategies are considered. However, it is possible that some members who would benefit from the testing, but do not meet criteria, will not receive an immediate approval for testing.